Chester County, PA, resident Kenneth “Ken” Pugh previously served as global franchise leader for the drug Voraxaze at biopharmaceutical firm BTG PLC. He led the drug to be accepted in the Centers for Medicare and Medicaid Services’ Net Technology Add-On Payment program, which raised BTG’s stature in the cancer care industry. Kenneth Pugh currently serves as a board member of Prohibix LLC.
Based in Philadelphia, Prohibix is developing a novel approach to arrest the development of heart failure for patients that have suffered heart attacks. As pointed out by the company, more than 3 million people in the United States are suffering from heart failure after experiencing a myocardial infarction (MI), also known as a heart attack. Over 600,000 people survive heart attacks annually. The economic burden of this situation translates to more than $30 billion per annum.
Present MI medical treatments such as bypass surgeries and coronary stents do not address the issue of changes that occur in the tissues that lead to heart failure. Contributing to tissue degradation is a class of enzymes known as matrix metalloproteinases (MMP). Prohibix has developed a technology for the local delivery of TIMP-3, an MMP inhibitor, to the affected heart muscle tissues through use of injectable hydrogels. Tests with large animals have shown superior results to other methods. The technology has been issued a patent, and there have been additional patent applications filed as well.
Based in Philadelphia, Prohibix is developing a novel approach to arrest the development of heart failure for patients that have suffered heart attacks. As pointed out by the company, more than 3 million people in the United States are suffering from heart failure after experiencing a myocardial infarction (MI), also known as a heart attack. Over 600,000 people survive heart attacks annually. The economic burden of this situation translates to more than $30 billion per annum.
Present MI medical treatments such as bypass surgeries and coronary stents do not address the issue of changes that occur in the tissues that lead to heart failure. Contributing to tissue degradation is a class of enzymes known as matrix metalloproteinases (MMP). Prohibix has developed a technology for the local delivery of TIMP-3, an MMP inhibitor, to the affected heart muscle tissues through use of injectable hydrogels. Tests with large animals have shown superior results to other methods. The technology has been issued a patent, and there have been additional patent applications filed as well.